A: For GLP-1 medications, follow-ups are recommended at 1-month intervals until you have reached a steady state, at which time you will meet with your provider every 3 months
Because we believe that supplying high-purity, research-grade peptides is only half of our commitment
Provider review required before fulfillment
other GLP-1 analogs Strong efficacy in animal models Favorable safety and pharmacokinetic profile Whats Next: Dual Trials in US and China Phase 1 trials will begin in the second half of 2025
Key Dates Include: Pre-release: December 4, 2024 Open for proposal submissions: January 8, 2025 DSIP Topic Q&A Closure: January 22, 2025, at 10:00 AM MT Close for proposal submissions: February 5, 2025, at 10:00 AM MT Participating DoD Components: Department of the Navy (Navy) Department of the Air Force (Air Force) Defense Health Agency (DHA) Missile Defense Agency (MDA) For further details on active topics and the submission process, you can explore the DoDs SBIR/STTR portal here
Standard oral glutathione has roughly 2030% bioavailability because digestive enzymes break the tripeptide (glutamate-cysteine-glycine) into constituent amino acids before absorption